A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation

@article{Olavarra2000API,
  title={A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation},
  author={Eduardo Olavarr{\'i}a and Moustapha Hassan and Alwyn Eades and Caroline Nilsson and Anthony Timms and John M. Matthews and Charles G. Craddock and Edward J Kanfer and Jane F. Apperley and John Goldman},
  journal={Leukemia},
  year={2000},
  volume={14},
  pages={1954-1959}
}
Busulfan has been previously only available in an oral formulation due to its poor water solubility. We report the results of a phase I study of multiple escalating doses of intravenous busulfan (Spartaject Busulfan, Orphan Europe, Paris, France) for myeloablation prior to stem cell transplantation (SCT) in 12 patients with chronic myeloid leukemia, acute myeloid leukemia or acute lymphocytic leukemia. One patient received allogeneic SCT; the other 11 patients received autologous SCT. The first… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 22 references

oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia

  • SP Dix, JR Wingard, +8 authors LT Heffner
  • Bone Marrow Transplant
  • 1997

Similar Papers

Loading similar papers…